Houston, TXNCT03007030Now EnrollingIRB Ready

CD30-Positive Neoplastic Cells Present Clinical Trial in Houston, TX

Access cutting-edge cd30-positive neoplastic cells present treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by M.D. Anderson Cancer Center

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access cd30-positive neoplastic cells present specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cd30-positive neoplastic cells present treatment provided free

Apply for This Houston Location

Check if you qualify for this cd30-positive neoplastic cells present clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This CD30-Positive Neoplastic Cells Present Study in Houston

This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.

Sponsor: M.D. Anderson Cancer Center

Who Can Participate

Inclusion Criteria

Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
Female subject is either: a. post-menopausal for at least one year before the screening visit; or b. surgically sterilized; or c. willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study and at least 6 months after the last dose of brentuximab vedotin
Male subject, even if surgically sterilized (i.e., status postvasectomy), agrees to use an acceptable barrier method for contraception (condom with a spermicidal agent), or completely abstain from heterosexual intercourse during the entire study treatment period through 6 months after the last dose of brentuximab vedotin
Absolute neutrophil count (ANC) \> 1500/mm\^3
Platelets \> 100,000/mm\^3
Hemoglobin (Hgb) \> 8.5 g/dL
Total bilirubin =\< 1.5 x upper limit of normal (ULN)
Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 3 x ULN; AST and/or ALT may be up to 5 X ULN if with known liver metastases (mets)
Calculated creatinine clearance must be \>= 30 mL/minute
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Pathologic diagnosis of malignant mesothelioma (any primary site is acceptable, any histology is acceptable)
Have unresectable malignant mesothelioma (any histology)
Positive CD30+ immunohistochemical expression
Any line of prior therapy - patients may be chemo-naive or chemo-refractory (any line)
Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration

Exclusion Criteria

Radiation therapy to more than 25% of the bone marrow; whole pelvic radiation is considered to be over 25%
Prior allogeneic bone marrow or organ transplantation
Female subject who is pregnant or breast-feeding; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for post-menopausal or surgically sterilized women
Patient has received other investigational drugs with 14 days before enrollment
Serious medical or psychiatric illness likely to interfere with participation in this clinical study
No prior history of malignancy within 2 years, unless cured of a skin cancer or a stage I-III solid tumor; no prior hematologic malignancy within 3 years
Known hypersensitivity to brentuximab vedotin components
Persons who are incarcerated at time of enrollment (e.g., prisoners) or likely to become incarcerated during the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT03007030) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

CD30-Positive Neoplastic Cells Present Treatment Options in Houston, TX

If you're searching for cd30-positive neoplastic cells present treatment options in Houston, TX, this clinical trial (NCT03007030) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cd30-positive neoplastic cells present specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cd30-positive neoplastic cells present clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Houston, TX

See all ankylosing spondylitis clinical trials recruiting in Houston — not just this study.

Browse Ankylosing Spondylitis Trials in Houston →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX